BR112012008861A2 - parvovírus, vacina, ácido nucleico isolado, composição imunogênica, método para provocar uma resposta imune em um animal contra a infecção por parvovírus, proteína vp-2 de parvovírus purificada, vetor de expressão, e método para exterminar células tumorais em um mamífero. - Google Patents

parvovírus, vacina, ácido nucleico isolado, composição imunogênica, método para provocar uma resposta imune em um animal contra a infecção por parvovírus, proteína vp-2 de parvovírus purificada, vetor de expressão, e método para exterminar células tumorais em um mamífero.

Info

Publication number
BR112012008861A2
BR112012008861A2 BR112012008861A BR112012008861A BR112012008861A2 BR 112012008861 A2 BR112012008861 A2 BR 112012008861A2 BR 112012008861 A BR112012008861 A BR 112012008861A BR 112012008861 A BR112012008861 A BR 112012008861A BR 112012008861 A2 BR112012008861 A2 BR 112012008861A2
Authority
BR
Brazil
Prior art keywords
parvovirus
vaccine
exterminating
eliciting
mammal
Prior art date
Application number
BR112012008861A
Other languages
English (en)
Inventor
Kapil Sanjay
Original Assignee
Univ Oklahoma State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oklahoma State filed Critical Univ Oklahoma State
Publication of BR112012008861A2 publication Critical patent/BR112012008861A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

parvovírus, vacina, ácido nucleico isolado, composição imunogênica, método para provocar uma resposta imune em um animal contra a infecção por parvovírus, proteína vp-2 parvovírus purificada, vetoir de expressão, e métodos para exterminar células tumorais em um mamífero - as preparações de vacina contra os parvovírus caninos são fornecidos. as vacinas incluem um novo parvovírus-2 canino isolado de um racum e ácidos nucleicos e proteínas relacionadas.
BR112012008861A 2009-10-14 2010-10-14 parvovírus, vacina, ácido nucleico isolado, composição imunogênica, método para provocar uma resposta imune em um animal contra a infecção por parvovírus, proteína vp-2 de parvovírus purificada, vetor de expressão, e método para exterminar células tumorais em um mamífero. BR112012008861A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25143209P 2009-10-14 2009-10-14
PCT/US2010/052677 WO2011047158A1 (en) 2009-10-14 2010-10-14 Isolation of a virus related to canine parvovirus-2 from a raccoon

Publications (1)

Publication Number Publication Date
BR112012008861A2 true BR112012008861A2 (pt) 2019-09-24

Family

ID=43876541

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012008861A BR112012008861A2 (pt) 2009-10-14 2010-10-14 parvovírus, vacina, ácido nucleico isolado, composição imunogênica, método para provocar uma resposta imune em um animal contra a infecção por parvovírus, proteína vp-2 de parvovírus purificada, vetor de expressão, e método para exterminar células tumorais em um mamífero.

Country Status (9)

Country Link
US (1) US8734808B2 (pt)
EP (1) EP2488634A4 (pt)
JP (1) JP2013507925A (pt)
CN (1) CN102971417B (pt)
AU (1) AU2010306752B2 (pt)
BR (1) BR112012008861A2 (pt)
CA (1) CA2777692A1 (pt)
RU (2) RU2565538C2 (pt)
WO (1) WO2011047158A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013507925A (ja) * 2009-10-14 2013-03-07 ザ・ボード・オブ・リージェンツ・フォー・オクラホマ・ステート・ユニバーシティ アライグマからのイヌパルボウイルス−２に関連するウイルスの分離
GB201404503D0 (en) * 2013-07-09 2014-04-30 Mars Inc Canine health product
CN106459928A (zh) 2014-04-17 2017-02-22 英特维特国际股份有限公司 猪细小病毒
MX2018004016A (es) 2015-09-29 2018-11-29 Merial Inc Vacunas de particulas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos.
CN108846258B (zh) * 2018-06-08 2021-05-18 中国人民解放军军事科学院军事医学研究院 一种自动检测分节段rna病毒重配的方法
CN110819735A (zh) * 2018-08-13 2020-02-21 北京美莱博医学科技有限公司 鉴定犬细小病毒的成套试剂和试剂盒
CN112877297A (zh) * 2021-03-27 2021-06-01 哈尔滨元亨生物药业有限公司 一种利用生物反应器制备猫瘟热病毒单克隆抗体的方法
RU2768749C1 (ru) * 2021-06-07 2022-03-24 Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") Средство специфической профилактики covid-19 для плотоядных животных

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193991A (en) 1978-12-20 1980-03-18 Cornell Research Foundation, Inc. Canine parvovirus vaccine
US4193990A (en) 1979-02-16 1980-03-18 Cornell Research Foundation, Inc. Heterotypic canine parvovirus vaccine
US4303645A (en) 1980-04-18 1981-12-01 Cornell Research Foundation, Inc. Modified living canine parvovirus vaccine
US4904468A (en) * 1987-06-08 1990-02-27 Norden Laboratories, Inc. Canine coronavirus vaccine
US5585254A (en) 1987-08-21 1996-12-17 University Of Colorado Foundation, Inc. Autonomous parvovirus gene delivery vehicles and expression vectors
US4971793A (en) 1988-05-09 1990-11-20 Boyce Thompson Institute For Plant Research, Inc. Subunit canine parvovirus vaccine
JP3602530B2 (ja) 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
ES2026826A6 (es) 1991-03-26 1992-05-01 Ercros Sa Procedimiento para la produccion de una vacuna subunidad contra el parvovirus canino y otros virus relacionados.
US5885585A (en) 1994-11-08 1999-03-23 Cornell Research Foundation, Inc. Attenuated canine parvovirus vaccine
EP0863151A1 (en) * 1997-02-12 1998-09-09 Akzo Nobel N.V. "Canine parvovirus dna vaccines"
CA2223029A1 (en) * 1997-02-12 1998-08-12 Akzo Nobel Nv Canine parvovirus dna vaccines
US20040265377A1 (en) * 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
RU2147609C1 (ru) * 1998-05-12 2000-04-20 Сазонкин Владимир Николаевич Штамм вируса canine parvovirus "риэль" для изготовления вакцины против парвовирусной инфекции плотоядных и вакцины "владивак" против вирусных болезней плотоядных на его основе
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
KR20050103215A (ko) * 2003-01-29 2005-10-27 화이자 프로덕츠 인코포레이티드 보르데텔라 브론키셉티카에 대한 개 백신
US7179456B2 (en) 2003-04-30 2007-02-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Use of parvovirus for brain tumor therapy
EP2170383A4 (en) * 2007-06-14 2012-12-26 Univ Oklahoma State GENETIC VARIANTS OF DOG PARVOVIRUS CONTAINING VACCINES
US8647637B2 (en) 2009-01-30 2014-02-11 The Board Of Regents For Oklahoma State University Immunogenic compositions, vaccines and diagnostics based on canine distemper viruses circulating in north american dogs
JP2013507925A (ja) * 2009-10-14 2013-03-07 ザ・ボード・オブ・リージェンツ・フォー・オクラホマ・ステート・ユニバーシティ アライグマからのイヌパルボウイルス−２に関連するウイルスの分離

Also Published As

Publication number Publication date
CN102971417A (zh) 2013-03-13
EP2488634A1 (en) 2012-08-22
RU2565538C2 (ru) 2015-10-20
US20120201848A1 (en) 2012-08-09
CN102971417B (zh) 2016-11-16
RU2012119494A (ru) 2013-11-20
EP2488634A4 (en) 2013-04-03
CA2777692A1 (en) 2011-04-21
US8734808B2 (en) 2014-05-27
RU2015113826A (ru) 2015-09-20
AU2010306752A2 (en) 2013-07-18
WO2011047158A1 (en) 2011-04-21
AU2010306752B2 (en) 2015-05-28
AU2010306752A1 (en) 2012-05-17
JP2013507925A (ja) 2013-03-07

Similar Documents

Publication Publication Date Title
BR112012008861A2 (pt) parvovírus, vacina, ácido nucleico isolado, composição imunogênica, método para provocar uma resposta imune em um animal contra a infecção por parvovírus, proteína vp-2 de parvovírus purificada, vetor de expressão, e método para exterminar células tumorais em um mamífero.
Loza-Rubio et al. Induction of a protective immune response to rabies virus in sheep after oral immunization with transgenic maize, expressing the rabies virus glycoprotein
US11085049B2 (en) Influenza virus-like particle production in plants
JP2022066209A (ja) Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
Rahn et al. Vaccines against influenza A viruses in poultry and swine: Status and future developments
BR112014014078A8 (pt) Composições compreendendo constructos genéticos il-12 aperfeiçoados e vacinas, imunoterapêuticos e métodos de usar os mesmos
BR112013020070A8 (pt) moléculas de ácido nucleico que codificam novos antígenos de herpes, vacina compreendendo as mesmas e métodos de uso das mesmas
WO2012135805A3 (en) Delivery and formulation of engineered nucleic acids
AR089797A1 (es) Vacunas contra clostridum difficile que comprenden toxinas recombinantes
NZ609903A (en) Expression vector for high level expression of recombinant proteins
BR112016007727A2 (pt) célula hospedeira, métodos para produzir um glicoconjugado, uma célula hospedeira e uma proteína n-glicosilada, para tratar ou prevenir uma infecção em um indivíduo e para induzir uma resposta imune em um indivíduo, glicoconjugado, kit, e, plasmídeo isolado
IL263643B (en) Air intake system for engines
RU2682752C2 (ru) Повышение выхода вирусоподобных частиц в растениях
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
EA202092990A2 (ru) Молекула нуклеиновой кислоты, кодирующая коровый белок вируса гепатита в, и вакцина, содержащая указанную молекулу
BR112017013595A2 (pt) cassete de expressão de dna recombinante, molécula de dna recombinante, vírus herpes de peru recombinante, célula hospedeira, métodos para construção de um vírus herpes de peru recombinante, para preparação de uma vacina, para prevenir ou reduzir infecção por vírus da doença bursal infecciosa e/ou vírus da doença de newcastle ou sinais associados de doença e para vacinação das aves, vacina para aves, e, usos de um cassete de expressão e de uma vacina.
BR112017012852A2 (pt) novo vírus de tilápia e usos do mesmo
BR112014008161A2 (pt) vírus da doença de marek não patogênico recombinante, método para a preparação do mesmo, molécula do ácido nucleico, célula hospedeira, vacina para aves domésticas, método para a preparação de uma vacina, uso de um vírus da doença de marek não patogênico recombinante, e, método de vacinação de aves domésticas
BR112015025898A2 (pt) polipeptídeo, célula, ácido nucleico, vetor, vírus da varíola suína recombinante, composição, vacina, e uso de um peptídeo sinal
BRPI0813313A8 (pt) Vetor poxvírus de racum recombinante, vacina da raiva recombinante, métodos para induzir uma resposta imunoprotetora para a raiva em um mamífero, e para produzir um vetor poxvírus de racum recombinante, e, plasmídeo pfd2003-gpv-pv.
BR112013013016A2 (pt) modulação de imunogenicidade de antígeno pela eliminação de epítopos reconhecidos pelas células nkt14
WO2013052814A8 (en) E1 enzyme mutants and uses thereof
BR112015024391A2 (pt) mutante de proteína, capsídeo, método para melhorar a estabilidade de um capsídeo, molécula de ácido nucleico isolada, célula hospedeira, micro-organismo recombinante carreador vivo, vacina, uso de um mutante da proteína vp2, e, métodos para preparar uma vacina e um mutante da proteína
Mooney et al. Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses
PE20121525A1 (es) Proteinas de union al receptor del factor 1 estimulante de colonias de macrofagos en aves

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.